rs162049 — MTRR

Intronic MTRR variant associated with reduced enzyme expression and impaired B12-dependent homocysteine remethylation

See your personal result for MTRR

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

MTRR rs162049 — The B12 Reactivation Support Variant

MTRR (methionine synthase reductase) is the enzyme that keeps methionine synthase 11 MTR: the enzyme that converts homocysteine to methionine using methylcobalamin (active B12) as a cofactor (MTR) running. During normal operation, MTR oxidizes its methylcobalamin cofactor to an inactive cob(II)alamin form — and it is MTRR's job to reduce it back to active methylcobalamin so MTR can continue. Without functional MTRR, MTR activity declines, homocysteine accumulates, and the methylation cycle slows.

rs162049 is an intronic variant — it sits within an intron of MTRR and does not directly change the protein sequence. Its significance lies in its membership in a functional haplotype: the G-allele risk haplotype is associated with reduced MTRR protein expression, meaning less enzyme is produced rather than less efficient enzyme. The net effect is the same: less B12 reactivation capacity, slower homocysteine remethylation, and altered DNA methylation patterns.

The Mechanism

The G allele at rs162049 co-segregates with a risk haplotype in the MTRR gene. Functional studies with transfected cell lines showed that this haplotype produced significantly lower MTRR protein levels compared to the wild-type haplotype, resulting in elevated homocysteine in culture medium and reduced LINE-1 methylation22 elevated homocysteine in culture medium and reduced LINE-1 methylation
Ohnami S et al. His595Tyr polymorphism in MTRR associated with pancreatic cancer risk. Gastroenterology, 2008 — a marker of global genomic methylation status. This is consistent with MTRR's central role: reduced B12 reactivation → reduced MTR activity → homocysteine accumulation → impaired one-carbon cycle → hypomethylation.

The Evidence

A multicenter Japanese case-control study 33 Ohnami S et al. Gastroenterology 2008 — 317 pancreatic cancer cases vs 1,232 controls identified rs162049 as an independent risk-associated variant for pancreatic cancer (OR 1.33, 95% CI 1.11–1.60; P = 0.0018). The association survived permutation testing under a recessive model (P = 0.024). A separate case-control study 44 Sangrajrang S et al. Breast Cancer Res Treat 2010 — 570 cases / 497 controls in Thai women in Thai women found that the G allele was associated with increased breast cancer risk in postmenopausal women (OR 1.61, 95% CI 1.07–2.44), consistent with impaired methylation-dependent gene regulation. A cross-sectional study 55 Ono H et al. Cancer Science 2012 — 384 Japanese women of 384 Japanese women found no independent effect of rs162049 on global leukocyte DNA methylation, suggesting the variant's functional impact may require haplotype context or additional environmental pressures (low B12, low folate intake).

The evidence overall is emerging: consistent biological plausibility and two independent cancer-risk associations, but no large-cohort homocysteine quantification or randomized intervention data specific to this variant.

Practical Implications

Because the G allele affects MTRR expression rather than enzyme structure, the intervention strategy focuses on reducing downstream demand rather than bypassing the enzyme. Ensuring sufficient methylcobalamin supply gives MTR more substrate to work with, partially compensating for reduced MTRR recycling capacity. Methylfolate (5-MTHF) keeps the methyl-donor pool full upstream. Monitoring plasma homocysteine provides an objective readout of whether the methylation cycle is under strain.

Interactions

rs162049 is most significant in combination with the MTRR A66G missense variant (rs1801394), which reduces enzyme efficiency — stacking reduced expression (rs162049) with reduced efficiency (rs1801394) compounds B12-reactivation impairment. Combined with MTHFR C677T (rs1801133), which limits methylfolate supply upstream, or MTR A2756G (rs1805087), which reduces methionine synthase activity directly, the effect on homocysteine clearance and DNA methylation is substantially amplified. The intronic SNP rs10380 (His595Tyr, MTRR) was co-identified in the same pancreatic cancer haplotype analysis and likely tags the same functional haplotype.

Nutrient Interactions

vitamin B12 increased_need
folate increased_need

Genotype Interpretations

What each possible genotype means for this variant.

AA Normal Expression Normal

Normal MTRR expression — B12 reactivation unaffected

Your MTRR gene produces enzyme at normal levels. B12 reactivation for methionine synthase runs efficiently, supporting normal homocysteine clearance and methylation capacity. About 62% of people globally share this genotype; it is the most common outcome.

AG Reduced Expression Intermediate

One G allele — modestly reduced MTRR expression

The G allele at rs162049 is part of a risk haplotype that produces less MTRR protein. With one copy of this haplotype, B12 reactivation capacity is modestly reduced. Methionine synthase (MTR) depends on continuous MTRR reactivation of its methylcobalamin cofactor — when this is slowed, homocysteine remethylation to methionine is less efficient. The effect in heterozygotes is typically subclinical but can become apparent when B12 intake is borderline or when combined with other methylation pathway variants.

GG Low Expression Reduced

Two G alleles — reduced MTRR expression and impaired B12 recycling

The homozygous GG genotype places you at the lower end of MTRR expression, meaning your cells produce less of this B12-reactivating enzyme. Functional cell-line studies using the risk haplotype showed elevated homocysteine and reduced LINE-1 methylation — a marker of genome-wide methylation status — compared to wild-type cells. The practical consequence is a methylation cycle that runs at reduced capacity, particularly under conditions of low B12 or folate intake, or when combined with impairment at other points in the one-carbon pathway (MTHFR, MTR, MTRR A66G).

The cancer-risk associations from observational data are consistent with the known biology: impaired MTRR function reduces SAM (the universal methyl donor) availability, reducing methylation of tumor-suppressor gene promoters and promoting genomic instability. However, no randomized intervention data exist specifically for rs162049 GG carriers, and the evidence overall remains emerging.